For research use only. Not for therapeutic Use.
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression[1].
LDCA (2-100 μM; 16-72 h) is used in combination with doxorubicin synergistically, enhances the growth inhibition and induces mitochondria-mediated apoptosis by recruiting the caspase cascade, restricting migration, and obviating the clonogenic outgrowth potential of melanoma cells[1].
LDCA (2 mg/kg, iv., the 6th day, once) is used in combination with doxorubicin thwarts tumor growth kinetics to restrain oncogenic progression, thus accentuating survival in the model of murine melanoma[1].
| Catalog Number | I043371 |
| CAS Number | 349106-80-5 |
| Synonyms | 2,2-dichloro-N-(3-chloro-4-fluorophenyl)acetamide |
| Molecular Formula | C8H5Cl3FNO |
| Purity | ≥95% |
| InChI | InChI=1S/C8H5Cl3FNO/c9-5-3-4(1-2-6(5)12)13-8(14)7(10)11/h1-3,7H,(H,13,14) |
| InChIKey | WZVDWCGCAQYINC-UHFFFAOYSA-N |
| SMILES | C1=CC(=C(C=C1NC(=O)C(Cl)Cl)Cl)F |
| Reference | [1]. Saha, Suchandrima, et al. The dual-hit metabolic modulator LDCA synergistically potentiates doxorubicin to selectively combat cancer-associated hallmarks. RSC Advances, 7(84), 53322–53333. doi:10.1039/c7ra08625c. |
